Elixir Medical's DynamX Bioadaptor Achieves 48% Reduction in Coronary Events in Landmark Trial
核心洞察
Elixir Medical (搜索)'s DynamX bioadaptor demonstrated a 48% reduction in target lesion failure compared to current-generation drug-eluting stents in a landmark clinical trial presented at TCT 2025.
The coronary implant showed significant benefits from six months through two years, with particular clinical advantages for high-risk patients with acute coronary syndrome.
The device addresses key limitations of traditional stents by unlocking and allowing arteries to return to natural motion after providing initial structural support.
Elixir Medical (搜索) announced breakthrough clinical results for its DynamX bioadaptor at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, demonstrating a 48% risk reduction in device-related cardiac events compared to current-generation drug-eluting stents. The findings represent the first interventional technology to show significant benefit with reduced long-term adverse events in two consecutive randomized controlled trials.
Landmark Clinical Outcomes
The DynamX bioadaptor achieved a 48% reduction in Target Lesion Failure (TLF) endpoint from six months through two years (HR: 0.52 [0.29–0.93], p=0.027) in prespecified landmark superiority analysis. TLF encompasses reductions in cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization.
Additional clinical benefits included a significant reduction in Target Vessel Failure (TVF) (p=0.048) from six months through two years in prespecified landmark analysis, and substantial clinical benefit for high-risk patients with Acute Coronary Syndrome (ACS) (p=0.018) over the same timeframe.
"The INFINITY-SWEDEHEART long-term landmark results confirm our trial design hypothesis, demonstrating separation of the event curves for Target Lesion Failure (TLF) at six months and maintaining consistency up to two years with a reduction of TLF by 48%," said Principal Investigator David Erlinge, M.D., Ph.D., Head of the Cardiology Department at Lund University, Lund, Sweden.
Addressing Persistent Stent Limitations
The results come amid renewed focus on coronary artery disease management, with cardiovascular disease affecting roughly 19% of the global population and remaining the world's leading cause of death. Despite widespread use of drug-eluting stents, in-stent restenosis and thrombosis after angioplasty continue to drive repeat interventions and adverse outcomes, contributing to worsening long-term patient prognosis and significant healthcare costs.
The DynamX bioadaptor directly addresses these stent-related issues through its unique mechanism of action. The device provides initial structural support before unlocking, adapting, and allowing the artery to heal and return to natural motion after fixated support is no longer needed—a key limitation of traditional drug-eluting stents.
Revolutionary Technology Design
The DynamX bioadaptor represents the first coronary implant technology designed to restore coronary artery hemodynamic modulation, as demonstrated by restored vessel pulsatility, compliance, and adaptive increase in blood flow volume, along with reduction in plaque progression. The device's bioabsorbable polymer dissolves over time, revealing a flexible structure that facilitates the artery's natural pulsatility and overall function.
According to Erlinge, the data validates "the unique property of the bioadaptor of restoring coronary physiology after unlocking after half a year, which translates into improved clinical outcomes long-term."
Regulatory Status and Market Position
The DynamX Sirolimus Eluting Coronary Bioadaptor System has received CE-mark approval in Europe and approval from the Japanese Pharmaceutical and Medical Device Agency (PDMA). The device also secured breakthrough device designation from the US Food and Drug Administration (FDA) in 2024, though it remains investigational in the United States.
The global coronary stent market is experiencing growth, with the sector estimated to reach $4.3 billion compared to $3.8 billion in 2024. Current market leaders include Medtronic, which generated $323 million in 2024, followed closely by Boston Scientific with $307 million in coronary stent sales.
The landmark results position Elixir Medical (搜索)'s technology as a potential paradigm shift in coronary interventions, offering the first significant advancement in stenting outcomes after two decades of limited progress in the field.